PBM
EYPT icon

Propel Bio Management’s EyePoint Inc EYPT Stock Holding History

Propel Bio Management’s Portfolio EYPT Stock Details EYPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74M Sell
191,745
-24,080
-11% -$322K 1.43% 22
2026
Q1 		$2.79M Buy
+215,825
New +$3.23M 1.76% 21

Other funds holding EYPT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Propel Bio Management's EYPT Position: Q2 2026 in Review

Propel Bio Management reduced its EyePoint Inc (EYPT) stake by 11% in Q2 2026, selling an estimated $322K and leaving 191,745 shares worth $2.74M. The position accounts for 1.43% of the portfolio, ranked #22.

Propel Bio Management first reported a position in EYPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.79M in Q1 2026. 189 funds tracked by Wall St. Rank hold EYPT as of Q2 2026.

  • Propel Bio Management held 191,745 shares of EyePoint Inc worth $2.74M as of Q2 2026.
  • Propel Bio Management sold 24,080 EyePoint Inc shares in Q2 2026, an estimated $322K.
  • EyePoint Inc made up 1.43% of Propel Bio Management's portfolio in Q2 2026, its #22 holding.
  • Propel Bio Management first reported a position in EyePoint Inc in Q1 2026 and has held it in 2 quarters since.
  • Propel Bio Management's EyePoint Inc position peaked at $2.79M in Q1 2026.
  • 189 funds tracked by Wall St. Rank held EyePoint Inc as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.